Back

Genotypic identification of polyclonal plasma cells in plasma cell dyscrasias shows an aberrant single-cell phenotype with clinical implications

Da Via, M. C.; Lazzaroni, F.; Matera, A.; Marella, A.; Maeda, A.; De Magistris, C.; Pettine, L.; Fabris, S.; Pioggia, S.; Marchetti, A.; Barbieri, M.; Lonati, S.; Cattaneo, A.; Tornese, M.; Scopetti, M.; Latifinavid, N.; Castellano, G.; Torricelli, F.; Neri, A.; Fokkema, C.; Cupedo, T.; Lionetti, M.; Passamonti, F.; Bolli, N.

2024-05-27 cancer biology
10.1101/2024.05.26.595470 bioRxiv
Show abstract

Multiple Myeloma (MM) is driven by clonal plasma cell (PC)-intrinsic factors and changes in the tumorigenic microenvironment (TME). To investigate if residual polyclonal PCs (pPCs) are disrupted, single-cell (sc) RNAseq and sc B-cell receptor analysis were applied in a cohort of 46 samples with PC dyscrasias and 18 healthy donors (HDs). Out of n=213,074 CD138pos PCs, 42,717 were genotypically identified as pPCs. Compared to HDs, we detected quantitative and qualitative differences in pPCs of patients showing immunoparesis, where we showed a pro-inflammatory status, driven by specific cellular interactions with TME. Finally, we derived a "hPC signature" that, once inferred in the CoMMpass dataset, was predictive of PFS and OS. Our findings show that genotypic, single-cell identification of pPCs in PC dyscrasias has relevant pathogenic and clinical implications.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.